Imatinib mesylate is a BCR-ABL tyrosine kinase inhibitor used in the management of chronic myeloid leukemia. It is a safe and well-tolerated agent with a few manageable side effects. We are reporting a case of imatinib-related fatal bone marrow aplasia after complete cytogenetic response.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
bone marrow
8
marrow aplasia
8
aplasia complete
8
complete cytogenetic
8
cytogenetic response
8
chronic myeloid
8
myeloid leukemia
8
imatinib-related bone
4
response chronic
4
leukemia imatinib
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!